Maria Serova

Oct 16, 2024 | radcliffecardiology.com | Aleksandra Bykova |Maria Serova |Maria Chashkina

Published content on this site is for information purposes and is not a substitute for professional medical advice. Where views/opinions are expressed, they are those of the author(s) and not of Radcliffe Medical Media. Radcliffe Cardiology is part of Radcliffe Medical Media, an independent publisher and the Radcliffe Group Ltd. It is not affiliated with or is an agent of, the Oxford Heart Centre, the John Radcliffe Hospital or the Oxford University Hospitals NHS Foundation Trust group.

Oct 15, 2024 | radcliffecvrm.com | Mikhail Kosiborod |Maria Serova |Maria Chashkina |John McMurray

Video Published: Views: 44 Likes: 0 Average (ratings) HFSA 24 - We are joined virtually by Dr Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, US) to discuss findings from the STEP-HFpEF trial programme in regard to the efficacy of semaglutide according to frailty status, and exercise function at baseline. Interview Questions:1. Could you remind us of the importance of STEP-HFpEF2. What was the study design and patient population? 3.